INTRALESIONAL RITUXIMAB SUPPLEMENTED WITH AUTOLOGOUS SERUM IN RELAPSED CD20+ INDOLENT LYMPHOMAS OF THE CONJUNCTIVA: ACTIVITY AND SAFETY RESULTS OF THE "IRIS" TRIAL. (12th June 2019) - Ferreri, A.J.; Sassone, M.; Miserocchi, E.; Govi, S.; Cecchetti, C.; Corti, M.E.; Calimeri, T.; Perrone, S.; Mappa, S.; Ponzoni, M.; Modorati, G.